Tsumura Ryoukeijutsukanto : 42 sachets(for two weeks)
|Manufacturer||TSUMURA & CO.|
|Brand||TSUMURA & CO.|
|Shipping Schedule||about 3 weeks after payment|
Ryokeijutsukanto is indicated for the relief of the following symptoms of those patients with dizziness, light-headed feeling, and pulpitation accompanied by decreased urine volume:Nervousness, neurosis, dizziness, heart pounding, shortness of breath, and headache
7.5 g (3sachets for 1day) of TSUMURA Ryokeijutsukanto extract granules contains 1.5 g of a dried extract of the following mixed crude drugs.JP Poria Sclerotium 6.0 gJP Cinnamon Bark 4.0 gJP Atractylodes Lancea Rhizome 3.0 gJP Glycyrrhiza 2.0 g(JP: The Japanese Pharmacopoeia)
Ryokeijutsukanto is indicated for the relief of the following symptoms of those patients with dizziness, light-headed feeling, and pulpitation accompanied by decreased urine volume: Nervousness, neurosis, dizziness, heart pounding, shortness of breath, and headache
The usual adult dose is 7.5 g/day orally in 2 or 3 divided doses before or between meals. The dosage may be adjusted according to the patient's age and body weight, and symptoms.
(1) When this product is used, the patient’s “SHO” (constitution/symptoms) should be taken into account. The patient’s progress should be carefully monitored, and if no improvement in symptoms/findings is observed, continuous treatment should be avoided. (2) Since this product contains Glycyrrhiza, careful attention should be paid to the serum potassium level, blood pressure, etc., and if any abnormality is observed, administration should be discontinued. (3) When this product is coadministered with other Kampo-preparations (Japanese traditional herbal medicines), etc., attention should be paid to the duplication of the contained crude drugs. SHO: The term “SHO” refers to a particular pathological status of a patient evaluated by the Kampo diagnosis, and is patterned according to the patient’s constitution, symptoms, etc. Kampo-preparations (Japanese traditional herbal medicines) should be used after confirmation that it is suitable for the identified “SHO” of the patient.